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1078–5884/00Comparison of Carbon-impregnated and Standard ePTFE
Prostheses in Extra-anatomical Anterior Tibial Artery
Bypass: A Prospective Randomized Multicenter Study
X. Kapfer,1 W. Meichelboeck2* and F.-M. Groegler31Department of Thoracic and Vascular Surgery, University Hospital Ulm, Ulm, 2Birkenallee 58, 82349
Pentenried, and 3Department of Vascular and Thoracic Surgery, Oberschwaben Klinik gGmbH, Ravensburg,
GermanyObjectives. The aim of this study was to find out whether carbon impregnated ePTFE vascular grafts have better long-term
patency or limb salvage rates than Standard ePTFE vascular grafts in crural revascularization in patients with chronic
critical ischemia.
Design. Prospective randomized multicenter trial. Study endpoints were 36 months follow-up, major amputation or death.
Materials. We used 6 mm carbon ePTFE (Carboflow) and 6 mm standard ePTFE vascular grafts (both C.R. BARD
Inc./IMPRA).
Methods. From June 1995 to November 1998, 283 patients were randomly assigned either to carbon (C) (nZ140) or to
standard (St) ePTFE (nZ143) vascular grafts at 19 centres. A standard protocol was used with lateral extra-anatomic
course of the graft to the anterior tibial artery and of a distal vein patch or cuff. More than 90% of the patients had rest pain or
gangrene.
Results. Two hundred and sixty-five (CZ130; StZ135) patients could be analysed in the intention-to-treat (ITT) group.
Primary patency, secondary patency and limb salvage rates after 36 months were 33, 43 and 67% in the carbon– and 30, 38
and 58% in the standard PTFE group, respectively, (log-rank test: pZ0.20, 0.12 and 0.16). Additional analyses were made
per protocol (PP) and as-treated (AT). The retrospective power of the study was calculated as 79 and 83%.
Conclusion. The ITT, PP and ATanalysis, showed no statistically significant advantage of the carbon ePTFE vascular graft
in terms of patency or limb salvage over the standard ePTFE vascular graft at 36 months.Keywords: Prospective randomized multicentric trial; Polytetrafluoroethylene; Crural bypass, extraanatomic; Biomaterials,
Carbon; Anterior tibial artery; Peripheral arterial occlusive disease (pAOD); Chronic critical ischemia.Introduction
The results of crural artery reconstruction in
patients with critical ischemia of the lower limbs
is often unsatisfactory.1–4 The use of autologous
great saphenous vein is recognized as gold stan-
dard.5–7 If vein is unsuitable or absent, prosthetic
material is generally used when there is danger that
amputation will be necessary.1,4 A technological
approach to improve the patency rate is to reduce
the thrombogenicity of the implant material. Use of
carbon as addition to ePTFE is one possibility. The
additive use of carbon with implants has
been explored since the early 1960s.8–10 Owing to its
excellent biocompatibility, carbon is used in implanting author. W. Meichelboeck, Dipl.-Ing., Birkenallee 58,
ried, Germany.
: wolfgang.meichelboeck@t-online.de
0155 + 14 $35.00/0 q 2006 Elsevier Ltd. All rights resermaterials for various medical applications and has
been associated with reduced thrombogenicity.11–21 In
animal studies carbon-coated vascular prostheses
demonstrate better patency rates18,22–25 but the coat-
ing of PTFE with carbon has proven impractical due
to the detachment of carbon particles from the
surface.26,27
The ePTFE carbon vascular prosthesis (Carboflow)
used in the present study is a modification of the
standard ePTFE vascular prosthesis (both C.R. Bard
Inc./IMPRA, USA). Carbon particles have been
permanently integrated into ePTFE structure by
means of a special manufacturing process based
on co-extrusion. The carbon thus becomes an
integral insoluble constituent of approximately 25%
of the ePTFE structure.27–29 Several animal exper-
iments have been carried out with this new ePTFE
carbon vascular prosthesis.27,30–32 The results ofEur J Vasc Endovasc Surg 32, 155–168 (2006)
doi:10.1016/j.ejvs.2005.12.015, available online at http://www.sciencedirect.com onved.
X. Kapfer et al.156Tsuchida et al.27 and of Babatasi et al.31 revealed a
significantly reduced thrombogenicity in the early
post-operative phase. However, Akers et al. (1993)30
and Ao et al.(2000)32 did not detect a difference.
Up to the beginning of the present study, one
prospective randomized trial of distal bypass and two
in vascular access had been reported utilising Carbo-
flow.33–36 Bacourt et al. reported encouraging results of
the patency and limb salvage rates for the ePTFE
carbon vascular prosthesis, however, a statistically
significant difference could not be shown.33,34 Trials of
Carboflow in vascular access have not found a
difference in outcome.35,36
The objective of the present study was to test
whether the carbon prosthesis has a clinical advan-
tage with regard to cumulative primary and
secondary patency or limb salvage rates in a larger
very homogenous patient population with peripheral
arterial disease (pAOD) and chronic critical ischemia.Materials and Methods
Participating centers of various sizes from Germany
and Austria were chosen (ranging from university to
county hospitals) in order to ensure a representative
cross section (Table 1). To include a homogenous
patient population, special care was taken to standar-
dize the outflow tract exclusively via the anterior tibial
artery and to standardize operation technique by
restricting to lateral extra-anatomic course of the
bypass only,37,38 with obligatory application of a distal
vein patch/cuff.Table 1. Participating centers and number of randomized patients (n
Name City
Nestle´, Salzmann Bad Nauheim
Albiker, Stockmann Berlin
Kindl, Schwilden Esslingen
Altsta¨dt Gu¨tersloh
Schro¨der, Riepe, Imig Hamburg–Harburg
Dragojevic Hannover
Bruckschlegl Heidenheim
Mu¨ller–Reinartz, Husfeldt Karlsruhe
Hiemer, Uy, Gruß Kassel
Baumann, Mangold Lahr
Munteanu, Hamann Leonberg
Naundorf, Maurer Munich
Teßarek, Torsello Mu¨nster
Gro¨gler, Reinhuber Ravensburg
Haug Remscheid
Djibey, Glu¨cklich Rendsburg
Schareck Rostock
Kapfer, Orend, Sunder-Plassmann Ulm
Straßegger, Hagmu¨ller Vienna
Eur J Vasc Endovasc Surg Vol 32, August 2006Inclusion criteria
† Age over 18 years (adults only).
† Critical ischemia with rest pain and or necroses/
gangrene (Fontaine stage III and IV) or severe
claudication (Fontaine stage IIb) after unsuccessful
conservative treatment over at least 2 months.
† Indication for femoro-crural bypass with anterior
tibial artery as only or best suitable distal vessel.
† No suitable veins available to perform a venous
bypass (unsufficient length, diameter less than
3 mm or varicose).
† Arterial vascular inflow tract without hemodyna-
mically relevant stenoses.
The following further technical inclusion criteria and
post-operative anticoagulation regime has been defined for
both groups:
† Use of Carbon or Standard ePTFE vascular grafts
(Carboflow/Standard C.R. Bard Inc./IMPRA) to
eliminate any other technical difference but the
carbon impregnation.
† Proximal anastomosis to either: the limb of an
aorto-femoral or cross-over prosthetic bypass,
external iliac artery, common femoral artery,
superficial femoral artery or deep femoral artery.
† Lateral extra-anatomical course of the bypass.37,38
† Distal anastomosis to the anterior tibial artery.
† Obligatory vein patch technique at the distal
anastomosis with the following techniques: Linton
patch,39 Miller cuff,40 Taylor patch41 or St Mary’s
boot.42
† Intraoperative or post-operative angiogram for
quality control.)
Clinic n
William Harvey Klinik 19
Franziskus Krankenhaus 60
Sta¨dtische Kliniken Esslingen 23
Sta¨dtisches Krankenhaus Gu¨tersloh 3
Allgemeines Krankenhaus Harburg 5
Klinikum Hannover Heidehaus 1
Klinikum Heidenheim 14
Diakonissenkrankenhaus Karlsruhe 7
Diakonissen-Krankenhaus 5
Klinikum Lahr-Ettenheim 16
Kreiskrankenhaus Leonberg 15
Klinikum rechts der Isar 4
St Franziskus Hospital 14
Krankenhaus St Elisabeth 24
Sana Klinikum Remscheid 25
Kreiskrankenhaus Rendsburg 17
Klinikum der Universita¨t Rostock 1
Klinikum der Universita¨t Ulm 21
Wilhelminen Spital 9
Total 283
Carbon vs. Standard PTFE in Tibial Artery Bypass 157† Anticoagulation regime: perioperatively (primary)
with heparin, afterwards with warfarin or, when
contraindicated, Acetylsalicylacid (ASA).Exclusion criteria
† Proximal anastomosis to an axillo-femoral bypass.
† Acute ischemia.
† Life expectancy less than 3 years.
Exclusively ePTFE vascular prosthesis of 6 mm
diameter and thin-walled were chosen. The choice of
using prosthesis with or without external spiral
reinforcement was left to the operating surgeon due
to the extra-anatomic course of the bypass.
The randomization sequence was generated as a
block randomization (block size 2) using an SAS macro
generated by a contract biometric institute (METRO-
NOMIA GmbH, Munich). The randomization to either
a carbon or standard PTFE vascular graft was carried
out directly in the operating theatre by the surgeon just
before the operation who opened the double-sealed,
numbered envelopes in ascending order.
Post-operative follow-up examinations were made
at the time of discharge from hospital and after 3, 6, 12,
18, 24 and 36 months.
The following study endpoints of post-operative
follow-up were defined:
† Follow-up at 36 months,
† A major amputation or
† Death of the patient.
Additional follow-up examinations could be
carried out at any time following adverse events and
at the discretion of the managing physician. Further-
more, details on revision operations were documen-
ted. The data were entered on a triplicate print-
through form and sent at regular intervals to an
external independent contract biometric institute
(METRONOMIA GmbH, Munich). This contract
institute fulfils the quality norm ISO 9002 and works
in accordance with the usual GCP guidelines. Data
input was in a data bank environment with entry
masks specifically adapted to the documentation
forms. The data were entered twice by two members
of staff independently of each other, to rule out typing
errors. Discrepancies detected by tests of plausibility
were clarified by written queries to the investigators.
The data analysis was made by an experienced
biometrician using the SAS system (version 8) under
WINDOWS 2000.
Investigators and patients were not blinded to
treatment assignment after the sealed envelopes havebeen opened for the further duration of the study. The
external independent study statisticians/biometrician
saw unblinded data.
The number of cases needed was calculated on the
basis of the following assumptions:
In view of the encouraging results with carbon-
impregnated prostheses reported in the studies of
Bacourt, Tsuchida und Babatasi,27,31,34 a one-sided
hypothesis was formulated: ‘carbon-impregnated pros-
theses have better patency rates and attain better limb salvage
rates than standard ePTFE prosthesis’. Data reported in
the literature1,3–6,34,37,38 indicate that the primary
patency rate of the standard ePTFE grafts to crural
arteries is about 40% after 36 months. A difference of
15% was considered to be clinically relevant with
regard to the main parameter ‘primary patency rate’. A
power of 80% (b-errorZ0.2) and an a-error of 5%
enabled an evaluation of 135 patients per group. The
loss to follow-up rate that was assumed with 10% per
year. It was therefore, planned to recruit a total of 330
patients in two groups of 165 patients. The study
protocol was approved by ethics committees and
informed consent was delegated to the participating
centres. An interim analysis at 1 year did not show a
significant difference, thus the study was continued.
Differences between groups for nominal data were
tested with the chi-square test or Fisher’s exact test.
Continuous variables were investigated for group
differences using the t-Test for equality of means or
with the Mann–Whitney-U test. The primary outcome
measure primary and secondary patency and the limb
salvage rates of the groups were compared on a
univariate basis using life-table analysis and the log-
rank test. The primary analysis was made on an
intention-to-treat (ITT) basis. A per protocol (PP) and
an as-treated (AT/or treatment received) analysis were
also calculated. The ITT, AT and PP-analysis sets
included only patients who comply with the inclusion
criteria and have received one of the two graft types
evaluated (Fig. 1).43 A retrospective power analysis of
the final study has been performed.
The reporting standard according to Rutherford
et al.44 and the CONSORT statement45,46 were followed.ResultsRandomization, study flow, treatment groups
In the period from June 1995 to November 1998, 283
patients in 19 centres were allocated on a random basis
to bypass with either Carbon PTFE (nZ140 C) or
Standard PTFE (nZ143 St) prosthesis. Eight patientsEur J Vasc Endovasc Surg Vol 32, August 2006
Fig. 1. Flow diagram of the study acc. to CONSORT statement: randomization and analysis groups (C, carbon PTFE; St,
standard PTFE; ITT, intention-to-treat; PP, per protocol; AT, as-treated; m, month; LTFU, lost-to-follow-up/did not reach
defined study endpoints).
X. Kapfer et al.158were not further documented due to lack of com-
pliance of the participating centers (six for unknown
hospital-internal reasons, two received an ePTFE
prosthesis of another brand), one patient underwentEur J Vasc Endovasc Surg Vol 32, August 2006an amputation intra-operatively before receiving the
prosthesis.
Eleven patients (CZ2/StZ9) did not receive the
prosthesis assigned by the randomization due to
Table 2. Baseline demographics and vascular risk factors of the intention-to treat (ITT) groups at the date of operation. Pre-operative
Fontaine stage, pain-free walking distance and ankle-brachial-index
Carbon (nZ130) Standard (nZ135) p-value d.f.
Gender: n (%)
Male 60 (46%) 54 (40%) 0.32* 1
Female 70 (54%) 81 (60%)
Median age: (years) (range) 73 (37–91) 75 (49–90) 0.14† 1
Height: (cm) meanGSD 168G9 167G9 0.33† 1
Weight: (kg) meanGSD 70G12 67G13 0.05† 1
BMI: (kg/m2) meanGSD 24.6G3.7 23.7G4.0 0.07† 1
Vascular risk factors: n (%)
CHD 80 (63%) 84 (62%) 1.00‡ 1
Hypertension 85 (65%) 89 (63%) 1.00‡ 1
Hyperlipidemia 61 (47%) 52 (39%) 0.17‡ 1
Diabetes mellitus 60 (46%) 63 (47%) 1.00‡ 1
Smoking (acc. to Rutherford44): n (%)
None 86 (66%) 93 (69%) 0.91‡ 3
Not current 6 (5%) 7 (5%)
Current 37 (29%) 34 (25%)
No data 1 (1%) 1 (1%)
pAOD stage acc. to Fontaine: n (%)
IIb (severe claudication) 11 (8.5%) 7 (5.2%) 0.55‡ 2
III (rest pain) 43 (33.1%) 44 (32.4%)
IV (necrosis/gangrene) 76 (58.5%) 84 (62.2%)
Pain-free walking distance: (m) median (range)
(nZ205)
10 (0–115) 10 (0–160) 0.73§ 1
ABI index¶:
ABI treated limb (nZ239) median (IQR) 0.36 (0.13–0.50) (nZ114) 0.35 (0.14–0.53) (nZ125) 0.68§ 1
ABI untreated limb (nZ206) median (IQR) 0.75 (0.59–1.00) (nZ100) 0.70 (0.53–0.93) (nZ106) 0.06§ 1
(BMI, body-mass-index; CHD, coronary heart disease; ABI, ankle-brachial-index; SD, standard deviation; IQR, inter quartil range; d.f.,
degrees of freedom.
* Pearson chi-square test.
† t-test for equality of means.
‡ Fisher’s exact test.
§ Mann–Whitney-U test.
¶ Only ABI indices below 1.5 included.
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assigned graft (nZ4).
A further nine patients were excluded from all
analyses of the principal parameters owing to contra-
ventions of the inclusion criteria (CZ5: proximal
anastomosis at an axillo-femoral bypass nZ1, patients
already with contralateral extremity in study nZ4;
StZ5: no vein patch at distal anastomosis nZ2, patch
technique with PTFE nZ1, a priori candidate for
amputation nZ1). A complete flow diagram of the
study according to the CONSORT statement45,46 is
shown in Fig. 1.
A total of 265 patients entered the ITT (CZ
130/StZ135) and AT (CZ137/StZ128) population.
Fourteen patients were lost to follow-up (LTFU).
Thus two hundred and fifty-one patients reached
the defined study endpoints in the ITT and AT
analysis groups. The per protocol (PP) population
comprised 254 patients. Thirteen patients were
LTFU in the PP population, so that 241 patients
reached the defined evaluation endpoints in this
group.Demographic and clinical data
Table 2 show the demographic and clinical data of the
ITT population. More than 90% of the patients were in
Fontaine stages III (33%) and IV (60%) with rest pain
and/or necroses/gangrene. The parameter ‘walking
distance’ was not evaluated in 58 patients. This was
due to the patient being bedridden, requiring wheel-
chairs or because of a pre-existing contralateral
amputation (nZ15). The ankle-brachial-index (ABI)
according to the American Heart Association (AHA)
standards47 could be calculated for the affected side in
239 patients and for the unaffected side in 206 patients.
Pseudohypertensive values of more than 1.5 (e.g.
media sclerosis) were not considered48,49 (Table 2).
Previous ipsilateral arterial operations were
reported in 150 patients (57%), 69 of these in the
carbon group and 81 in the standard group (Fisher’s
exact test, pZ0.27). More than one-third of patients
(nZ99/37%, CZ44/StZ55) had undergone previous
infrainguinal bypass. An aorto-iliac operation had
been previously carried out in 23 (9%, CZ10/StZ13)Eur J Vasc Endovasc Surg Vol 32, August 2006
Table 3. Run-off: overview of all patients in the ITT group (nZ265)
Distal anterior tibial artery Plantar arch
Total n (%) Complete n (%) Incomplete n (%) Not assessed/no
assessment possible
n (%)
No data n (%)
Patent, without stenosis 169 (63.8%) 60 (22.6%) 65 (24.5%) 38 (14.3%) 6 (2,3%)
Patent, but stenosed 89 (33.6%) 6 (2.3%) 68 (25.7%) 12 (4.5%) 3 (1.1%)
Occluded 5 (1.9%) 2 (0.8%) 3 (1.1%)
No complete data 2 (0.8%) 1 (0.4%) 1 (0.4%)
Total 265 (100.0%) 66 (24.9%) 136 (51.3%) 53 (20.0%) 10 (3.8%)
Results of pre-operative angiographic assessment of the distal anterior tibial artery and the plantar arch.
X. Kapfer et al.160patients. Seventeen patients (7%, CZ10/StZ7) had
undergone aorto-iliac and infrainguinal reconstruc-
tions previously. No location has been specified in 11
(4%, CZ5/StZ6) of the cases. (Fisher’s exact test, 4
d.f., pZ0.64). Bypass implantation (nZ102) including
combinations with angioplasty/Stent and endarter-
ectomy were the most frequent form of previous
ipsilateral therapy. The remaining 48 patients had
angioplasty (nZ24), stents (nZ3) or endarterectomy
(nZ12) or non-specified procedures (nZ9), (Fisher’s
exact test, 5 d.f., pZ0.28).Outflow tract
Table 3 shows a complete overview on the run-off
status of the overall patient population, a moreFig. 2. Pre-operative angiographic run-off status of the anterior t
group (nZ265; ITT-analysis; Arcus, plantar arch; patent, patent
occluded, distal occlusion; values below 2% not numbered; Fis
Eur J Vasc Endovasc Surg Vol 32, August 2006detailed description of the outflow tract for the two
groups is shown in Fig. 2. The prognostic favourable
situation with distal patent anterior tibial artery and
simultaneous complete plantar arch was found in only
60 patients (23%). There was no difference in run-off
between the two groups in any of the four subgroups
shown in Fig. 2. (Fisher exact test, pO0.05 for the
groups and subgroups).Operation data and post-operative
anticoagulation/thromobocyte aggregation regime
There were no significant differences with regard to the
data of the surgical technique, such as operation time,
external spiral reinforcement used, location of the
proximal anastomosis, the kind of distal vein patchibial artery and plantar arch in the carbon and standard PTFE
-no relevant stenosis; stenosed, patent-but relevant stenosed;
her’s exact test pO0.05 for all groups and subgroups).
Table 4. Surgical technique, operative data, hospital stay–ITT
Carbon (nZ130) Standard (nZ135) p-value d.f.
Operation time: (min) median (IQR) 140 (115–185) 140 (106–180) 0.79* 1
Prosthesis with external spiral reinforcement: n (%)
Yes 79 (61%) 78 (58%) 0.71† 1
No 51 (39%) 57 (42%)
Location of proximal anastomosis: n (%)
Limb of aorto-femoral prosthesis 14 (11%) 15 (11%) 0.94† 5
External iliac artery 8 (6%) 7 (5%)
Common femoral artery 87 (70%) 94 (70%)
Superficial femoral artery 11 (9%) 13 (10%)
Deep femoral artery 9 (7%) 5 (4%)
No data 1 (1%) 1 (1%)
Type of distal vein patch technique: n (%)
Taylor patch 78 (60%) 80 (59%) 0.85† 3
Linton patch 45 (35%) 49 (36%)
St Mary’s boot 6 (5%) 4 (3%)
Miller cuff 1 (1%) 2 (2%)
Intraoperative Heparin, admin.: n (%)
Systemic 52 (40%) 57 (42%) 0.81† 3
Local 19 (15%) 23 (17%)
Systemic and local 57 (44%) 54 (40%)
No data 2 (2%) 1 (1%)
Intraoperative Heparin, dosage: I.U. median (IQR) 5.000 (5.000–7.500) 5.000 (5.000–7.500) 0.93* 1
Intraoperative angiogram: n (%) 86 (66%) 93 (69%) 0.60† 1
Immediate bypass occlusion (!24 h): n (%) 10 (8%) 14 (10%) 0.67† 1
Hospital stay, post op: (days), median (IQR) (nZ204);
(CZ26, StZ35 no data)
26 (16–35) 24 (17–41) 0.12‡ 1
d.f., degrees of freedom.
* Mann–Whitney-U test.
† Fisher’s exact test.
‡ t-test for equality of means.
Carbon vs. Standard PTFE in Tibial Artery Bypass 161technique, intraoperative administration of Heparin,
intraoperative angiogram, immediate bypass occlusion
and hospital stay (Table 4). Simultaneous procedures
on the inflow tract in the iliac region and the bifurcation
of the femoral artery were performed in 18 patients
(7%). This involved 11 endarterectomies, three
bypasses, one endarterectomy and bypass, two angio-
plasties and one type not specified. In nine patients
(CZ3/StZ6), 11 intraoperative complications were
documented. These included five venous injuries, three
dissections, two perforations and one plaque disrup-
tion. The two treatment groups did not differ with
regard to the occurrence of simultaneous procedures
(Fishers exact test, 4 d.f., pZ0.66) and intraoperative
complications (Fisher’s-exact test, 3 d.f., pZ0.33).
The status of the post-operative anticoagulation
was evaluated in 253 patients at the time of discharge
from hospital to check for group differences (five
patients were already deceased and seven had prior
major amputations within the hospital). In 55% (nZ
138) patients were receiving warfarin, 30% (nZ75) of
the patients were on Acetysalicylacid (ASA) and 11%
(nZ27) on heparin at this time. Five patients have
received ASA in combination with other anticoagula-
tion drugs (two ASACHeparin, three ASACTiplopi-
din). Five received other types of anticoagulation (oneLMWH, one Clopidogrel, one Danaparanoid-
Natrium, two Ticlopidin). No data on the applied
anticoagulation regime has been recorded for three
patients. There were no differences between the
groups (Fisher’s exact test, 10 d.f., pZ0.44).Redo procedure, infections, 30-days mortality rate:
Redo procedures were performed in 15 cases (nine
bypass explantations (2!30d/7O30d), six new
bypasses) (Fisher’s exact test, 2 d.f., pZ0.62). These
patients were rated as secondary occluded at the time of
the redo operation, even if the redo procedure was
successful.44 Thirteen (4.9%) bypass infections of which
3 (1.1%) have been before 30 days and five (1.9%)
seroma formations were recorded during the follow-up
period. 30-days mortality rate was 3.4% (nZ9).Patency and limb salvage rates analysis
The detailed data of the life table analysis of the
primary (PrimPat), secondary patency rates (SecPat)
and the limb salvage rate (LSalv) for the two groups
are shown in the figures (Figs. 3–5) and tables (Tables
5–7). At 36 months, 33% of grafts were still primaryEur J Vasc Endovasc Surg Vol 32, August 2006
Fig. 3. Life table curves for primary patency rate acc. to Rutherford et al.44, carbon- vs. standard-PTFE vascular grafts; ITT
analysis (log-rank test c2Z1.65, 1 d.f.; pZ0.20); standard-error!5% at all times; table indicates number of patients (n) at risk
at begin of each intervall.
X. Kapfer et al.162patent in the carbon group and 30% in the standard
group. The SecPat at 36 months was 43% in the carbon
group and 38% in the standard group. The LSalv was
67% in the carbon group and 58% in the standard
group. The 95% confidence intervals (95% CI) of both
groups did not overlap in SecPat between 6 and 12
months. During all other intervals for SecPat and in all
intervals for PrimPat and LSalv the 95% CI did overlap
(Tables 5–7 and Figs. 3–5). The obvious nominal
differences between 6 and 18 months in favour of the
carbon group did not lead to a statistically significant
difference. In our life table analysis results have been
curtained at 36 months as the number of remaining
patients at risk have reached only 20% (nZ54) of the
original patient population (nZ265). Results in these
later intervals are also biased by the high degree of loss
to follow-up.Comparison of the group evaluations and power analysis
The PP and AT analysis did not show any qualitative
difference from the ITT analysis (Table 8). The
alternative hypothesis according to which ‘carbon-
impregnated prosthesis have better patency or limb
salvage rates than standard ePTFE prostheses’ hence
could not be accepted. The null hypothesis (‘carbon-
impregnated prostheses do not have better patency orEur J Vasc Endovasc Surg Vol 32, August 2006limb salvage rates’) is valid for all three analysis
groups.
The retrospective power analysis of the ITT set
showed a power of 79%. For this computation the
sample size 265 patients (CZ130, StZ135) and the
observed lost-to-follow-up rate (5.3%, 14/265) was
used. That means that a study with 135 patients in the
control group and 130 in the treatment group has a
chance of 79% (Zpower) to show a difference between
a patency rate of 40% in the Standard PTFE group and
a patency rate of 55% in the Carbon PTFE group, using
a one-sided log-rank test with alpha equals 5%; given a
lost-to follow-up rate of 5.3%. When using the final
patency rate of 30.7% for the Standard group with a
15% difference for the Carbon group a power of 83%
was calculated for the ITT set. This means that the
study was large enough in order to detect a difference
of 15% points between carbon and standard PTFE
grafts in case this difference is true (but unknown). The
power analysis computations were performed with n
Query Advisor Version 5.0.Discussion
One of the main problems in crural bypass surgery is
choice or availability of suitable bypass material. The
autologous great saphenous vein (GSV) is the material
Fig. 4. Life table curves for secondary patency rate acc. to Rutherford et al.44, carbon- vs. standard-PTFE vascular grafts; ITT
analysis (log-rank test c2Z2.46, 1 d.f.; pZ0.12); standard-error!5% at all times; table indicates number of patients (n) at risk
at begin of each interval.
Carbon vs. Standard PTFE in Tibial Artery Bypass 163of first choice, but is unavailable in up to 28% of
patients owing to prior coronary bypass surgery,
varicose veins surgery, prior arterial reconstructions,
insufficient vein calibre and prior thrombophlebitis.50
In this prospective, randomized and multicenter
study, the effect of a physically and chemically
insoluble carbon impregnation of ePTFE prosthesis
on clinical outcome was investigated by comparison
with standard ePTFE prosthesis of the same kind. The
principal parameters evaluated were the primary
(PrimPat) and secondary patency rate (SecPat) and
the limb salvage rate (LSalv). Important factors
affecting these parameters are the outflow tract and
the kind of bypass procedure, which were tightly
controlled. Use of a vein patch technique at the distal
anastomosis39–42,51,52 was an indispensable prerequi-
site in the present study, but the technical implemen-
tation was left to the surgeon’s discretion in order to
rule out additional sources of technical error. With
these restrictions we have compared two very
homogeneous patient groups.
As suggested by Meichelbo¨ck in 2002,53 the outflow
tract was described in terms of the condition of the
anterior tibial artery and the hollow of the foot (Fig. 2).
Descriptive angiographic data enable a differentiated
evaluation of the outflow tract. Schweiger et al.3 also
point to the crucial significance of the outflow tract for
the prognosis of bypass extending beyond the kneejoint. The method suggested by Meichelboeck53
appeared to us to be more effective for practical
clinical use than the well-known appraisal of the
outflow tract according to Rutherford.44
By using a material with a reduced thrombogenicity
we would have expected differences in the early post-
operative phase up to 30 days. But we did not see any
difference in the immediate occlusion up the 24 h (Table
4) and in the further early course up to 30 days. In total
39% of all occlusions in the Carbon and 36% of all
occlusions in the Standard grafts occurred in the early
period up to 30 days, suggesting that a significant
number of graft failures could be related to technical
problems. Less occlusions in favour of the carbon
prosthesis were recorded in the period between one
and 6 months. In the interval between 6 and 18 months
the life table curves of both groups run almost parallel,
while the standard PTFE prosthesis seems to have a
quantitative advantage later than 18 months (Figs. 3–5).
The life tables for PrimPat, SecPat and LSalv
presented are shown consistently in accordance with
the revised Rutherford recommendations.44 All cumu-
lative patency calculations were made not at the
beginning of an interval, but at the end. This leads to
a formal worsening of the results, but gives a more
precise picture of the actual course. Consequently, our
results cannot be compared directly with ‘former’
literature, which has been calculated according theEur J Vasc Endovasc Surg Vol 32, August 2006
Fig. 5. Life table curves for limb salvage rate acc. to Rutherford et al.44, carbon- vs. standard-PTFE vascular grafts; ITT analysis
(log-rank test c2Z1.96, 1 d.f.; pZ0.16); standard-error!5.3% at all times; table indicates number of patients (n) at risk at begin
of each interval.
X. Kapfer et al.164recommended standards of Rutherford 198654 at the
beginning of each interval.
In a meta-analysis, Albers et al.55 showed pooled
results for PTFE bypass to infrapopliteal arteries for
primary patency (nZ40 studies), secondary patency
(nZ35 studies) and limb salvage (nZ31 studies). The
results at 36 months were 41, 51 and 66%, respectively.Table 5. Life tables primary patency rate according to Rutherford et
c2Z1.65, 1 d.f.; pZ0.20) (LTFU, lost-to-follow-up; CI, confidence inte
Interval
(month)
No. at risk
at start of
interval (n)
No. failed
during
interval (n)
Withdrawn during interv
due to
Death LTFU
Carbon PTFE
0–1 130 27 5 2
1–3 96 10 6 2
3–6 78 5 1 2
6–12 70 7 7 1
12–18 55 8 3 0
18–24 44 9 1 0
24–36 34 5 3 0
Total 71 26 7
Standard PTFE
0–1 135 31 2 3
1–3 99 14 4 1
3–6 80 15 2 0
6–12 63 11 5 0
12–18 47 6 2 2
18–24 37 3 1 1
24–36 32 4 0 0
Total 84 16 7
Eur J Vasc Endovasc Surg Vol 32, August 2006However, it was shown that there is a marked difference
in the results for PrimPat, SecPat and LSalv between
‘qualitatively good’ and ‘qualitatively less good’
studies. In a total of 43 publications investigated, only
ten reported on a patient number in excess of 100. Of
these, only five3,56–59 attained a rating of more than 10
points in quality scoring used (maximum 14 points).al.44, carbon vs. standard PTFE vascular grafts, ITT (log-rank test
rval)
al (n) Interval
failure rate
Cumulative
patency rate,
(95% CI%)
Standard
error (%)
Duration
0 0.2134 78.7% (72.4–84.9) 3.2
0 0.1087 70.1% (62.4–77.8) 3.9
0 0.0654 65.5% (57.0–74.1) 4.4
0 0.1061 58.6% (49.8–67.4) 4.5
0 0.1495 49.8% (40.5–59.1) 4.8
0 0.2069 39.5% (30.4–48.6) 4.6
0 0.1538 33.4% (24.3–42.6) 4.7
0
0 0.2340 76.6% (70.3–82.6) 3.2
0 0.1451 65.5% (57.9–73.1) 3.9
0 0.1899 53.1% (45.1–61.0) 4.1
0 0.1818 43.4% (35.4–51.5) 4.1
0 0.1333 37.6% (29.1–46.1) 4.3
0 0.0833 34.5% (25.5–43.5) 4.6
0 0.1250 30.2% (21.4–38.9) 4.5
0
Table 6. Life tables secondary patency rate, according to Rutherford et al.44, carbon vs. standard PTFE vascular grafts, ITT (log-rank test
c2Z2.46, 1 d.f.; pZ0.12) (LTFU, lost-to-follow-up; CI, confidence interval)
Interval
(month)
No. at risk
at start of
interval (n)
No. failed
during
interval (n)
Withdrawn during interval (n)
due to
Interval
failure
rate
Cumulative patency
rate, (95% CI%)
Standard
error (%)
Death LTFU Duration
Carbon PTFE
0–1 130 15 5 2 0 0.1186 88.1% (82.9–93.4) 2.7
1–3 108 9 6 2 0 0.0865 80.5% (73.8–87.2) 3.4
3–6 91 5 3 2 0 0.0565 76.0% (68.3–83.6) 3.9
6–12 81 10 7 1 0 0.1299 66.1% (57.7–74.5) 4.3
12–18 63 7 3 0 0 0.1138 58.6% (49.3–67.9) 4.8
18–24 53 7 1 0 0 0.1333 50.8% (41.2–60.4) 4.9
24–36 45 7 3 0 0 0.1609 42.6% (33.2–52.0) 4.8
Total 60 28 7 0
Standard PTFE
0–1 135 23 2 3 0 0.1736 82.6% (76.8–88.5) 3.0
1–3 107 11 4 1 0 0.1053 73.9% (66.8–81.1) 3.7
3–6 91 19 2 0 0 0.2111 58.3% (50.6–66.1) 4.0
6–12 70 10 5 0 0 0.1481 49.7% (41.4–58.0) 4.2
12–18 55 5 3 2 0 0.0952 45.0% (36.1–53.8) 4.5
18–24 45 3 1 1 0 0.0682 41.9% (32.6–51.2) 4.8
24–36 40 4 2 0 0 0.1026 37.6% (28.4–46.8) 4.7
Total 75 19 7 0
Carbon vs. Standard PTFE in Tibial Artery Bypass 165In their extensive retrospective study of 1993, Schwei-
ger et al.3 were able to demonstrate a cumulative
PrimPat and SecPat of 37 and 45%, respectively, at 3
years. If these calculations are considered in terms of the
latest Rutherford criteria,44 they would be reduced to 31
and 38%, respectively, comparable with our own
results. The cumulative LSalv was 63% after 2 years
and 51% after 5 years.
The results of Bacourt33,34 for Carbon vs. Standard
PTFE at 24 months were 45 vs. 35% (PrimPat), 53 vs.Table 7. Life tables limb salvage rate according to Rutherford et al.44
1.96, 1 d.f.; pZ0.16) (LTFU, lost-to-follow-up; CI, confidence interval
Interval
(month)
No. at risk
at start of
interval (n)
No. failed
during
interval (n)
Withdrawn during in
due to
Death LTFU
Carbon PTFE
0–1 130 10 5 1
1–3 114 6 6 3
3–6 99 3 5 1
6–12 90 6 9 1
12–18 74 2 4 1
18–24 67 5 1 0
24–36 61 3 5 0
Total 35 35 7
Standard PTFE
0–1 135 9 3 3
1–3 120 12 7 0
3–6 101 8 5 1
6–12 87 9 11 0
12–18 67 4 5 2
18–24 56 2 2 1
24–36 51 3 4 0
Total 47 37 736% (SecPat) and 57 vs. 47% (LSalv). These results
compare with our 24 months data with 40 (C) vs. 35%
(St), 51 vs. 42% and 71 vs. 62%.
In 2001 Lang et al.60 presented results of a
prospective randomized study with more than 200
patients of Carbon PTFE vs. Standard PTFE bypass,
but confined exclusively to the below knee popliteal
segment. No statistically significant difference could
be found in the per protocol analysis in this study. The
results for PrimPat, SecPat and LSalv for carbon vs., carbon vs. standard PTFE vascular grafts, ITT (log-rank test c2Z
)
terval (n) Interval
failure
rate
Cumulative
patency rate,
(95% CI%)
Standard
error (%)
Duration
0 0.0787 92.1% (87.7–96.6) 2.3
0 0.0548 87.1% (81.3–90.9) 2.9
0 0.0313 84.4% (77.8–90.8) 3.4
0 0.0706 78.4% (70.9–85.9) 3.8
0 0.0280 76.2% (67.7–84.7) 4.3
0 0.0752 70.5% (61.3–79.7) 4.7
0 0.0513 66.7% (57.2–76.5) 4.9
0
0 0.0682 93.2% (89.1–97.3) 2.1
0 0.1030 83.6% (77.6–89.6) 3.1
0 0.0816 76.8% (69.5–84.0) 3.7
0 0.1104 68.3% (60.2–76.4) 4.1
0 0.0630 64.0% (54.8–73.2) 4.7
0 0.0367 61.6% (51.6–71.6) 5.1
0 0.0612 57.9% (47.6–68.2) 5.3
0
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Table 8. Log-rank test analysis at 36 months of the life table curves
for the three different analysis groups. (ITT, intention-to-treat; PP,
per protocol und; AT, as-treated)
Analysis
group
Primary
patency
p-value
Secondary
patency
p-value
Limb
salvage
p-value
ITT (nZ265) 0.20 0.12 0.16
PP (nZ254) 0.23 0.18 0.23
AT (nZ265) 0.29 0.28 0.34
X. Kapfer et al.166standard PTFE at 36 months were 36 vs. 35%, 46 vs.
45% and 60 vs. 63%, respectively. The detailed final
results are currently being prepared for publication.61
While the coating with Carbon in mechanical heart
valves is standard today as surface treatment to
achieve higher mechanical stability, it did also not
lead to clinical improved results in other implants with
blood contact such as stents,62–64 although the results
for carbon coating were encouraging in terms of
biocompatibility, hemocompatibility and decreased
thrombogenicity evaluated in vitro, in animal trials
and in non-randomized clinical settings.65–69
The apparent advantage in the carbon group in our
study in the period from six to 18 months is
noteworthy and might be of clinical importance for
individual patients, but seems to be a temporary effect.
However, any single point on a survival curve is not a
particularly reliable representation of survival at that
time; it is the entire curve which is a reliable
representation of survival, thus the entire curves
should be compared, not a single point on the curve.
Our hypothesis that PrimPat, SecPat and the LSalv
rate are better for the Carbon prosthesis was refuted.
At 36 months, Carbon PTFE prosthesis and Standard
PTFE prosthesis had similar outcomes. This finding
was confirmed with additional calculations based on
the ‘per protocol’ (PP) and ‘as-treated’ (AT) groups,
with reasonable power to show an effect (79 and 83%,
respectively). Overall this suggests that reduction of
graft thrombogenicity with a non-pharmacological
method will not result in a crucial clinical advance in
treatment of this group of patients evaluated in the
long term without further additional measures.
Alternative mechanisms and conduits needed to be
evaluated in proper prospective randomized studies
for the group of patients with no autologous vein
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